Davis Polk advised the lead placement agent in connection with I-Mab’s $418 million private placement of 29,133,502 ordinary shares and warrants to subscribe for 5,341,267 ordinary shares.

I-Mab is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. Its mission is to bring transformational medicines to patients around the world through innovation.

The Davis Polk capital markets team included partner Yasin Keshvargar and associate David Li. All members of the Davis Polk team are based in the New York office.

Copy link to share post